AI Science Tracker
EN

Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea

1 discovery from 2024

Discoveries

Identification of VWA5A as a novel biomarker for inhibiting metastasis in breast cancer by machine-learning based protein prioritization

Source check: Source checked. Not independent scientific confirmation.

Finding / tested result: A machine-learning recursive feature-addition/LOOCV workflow prioritized VWA5A from a 29-patient breast-cancer proteomics discovery set; its association with disease-free survival was examined in METABRIC (n=1,904; HR 0.71, 95% CI 0.58–0.85), with weaker discrimination (c-index 0.543). This supports an exploratory biomarker candidate, not causal inhibition or clinical utility.

Technology: Recursive feature-addition machine-learning workflow

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
Recursive feature-addition machine-learning workflow
Limitation / still unknown
The reported association does not establish causation; transfer beyond the stated cohorts and any practical benefit were not established.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://www.nature.com/articles/s41598-024-53015-1 · https://doi.org/10.1038/s41598-024-53015-1

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open the interactive profile for the timeline, or browse all organizations and model families.